DexCom’s performance in the quarter was strong, with total revenue increasing by 20%. By the end of 2022, the company had over 1.7 million clients worldwide after adding nearly 450,000 new Dexcom users. The management delivered an all-around beat and claims to have increased consumer engagement and growth while expanding the scope and effectiveness of its business. It was successful in maintaining adequate supply in a challenging economic climate and offering more than 99% on-time delivery rates. The company started a complete rollout outside of the US after receiving regulatory approval from the CE Mark and FDA for G7. The new features, including a 60% smaller form factor, a quicker warm-up time, and user-friendly interface, are received well by customers. We give DexCom a ‘Hold’ rating with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $99 annual subscription!